Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00055227.xml
Nephrologie aktuell 2024; 28(03): 116-123
DOI: 10.1055/a-2214-3093
DOI: 10.1055/a-2214-3093
Schwerpunkt
Nephrologie
Diabetische Nephropathie und Progressionsverlangsamung der CKD
Portfolio zur Therapie der diabetischen Nephropathie
ZUSAMMENFASSUNG
Die Verlangsamung des Krankheitsverlaufs bei chronischer Nierenkrankheit (CKD: „chronic kidney disease“) stellt eine wesentliche, wenn nicht die wesentlichste Aufgabe von Nephrologinnen und Nephrologen dar. Aufgrund der Häufigkeit von Diabetes mellitus kommt der diabetischen Nephropathie dabei ein bedeutender Stellenwert zu. Erfreulicherweise haben sich in den letzten Jahren zahlreiche Neuerungen in Bezug auf therapeutische Möglichkeiten ergeben. Dieser Artikel fasst sowohl altbekannte als auch neue Behandlungsmethoden zur Progressionsverlangsamung der diabetischen Nephropathie zusammen.
Publication History
Article published online:
19 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Saran R, Robinson B, Abbott KC. et al US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2019; 73: A7-A8 DOI: 10.1053/j.ajkd.2019.01.001.
- 2 Cho NH, Shaw JE, Karuranga S. et al IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271-281 DOI: 10.1016/j.diabres.2018.02.023.
- 3 Brijesh M, Saurav P. Comparative Study of Significance of Serum Cystatin-C, Serum Creatinine and Microalbuminuria Estimation in Patients of Early Diabetic Nephropathy. J Diabetes Metab 2015; 06: 490 DOI: 10.4172/2155-6156.1000490.
- 4 U. S. Dept of Health and Human Services – Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. Im Internet. www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf Stand 17.01.2023
- 5 Johansen KL, Chertow GM, Foley RN. et al US Renal Data System 2020 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis 2021; 77: A7-A8 DOI: 10.1053/j.ajkd.2021.01.002.
- 6 Afkarian M, Zelnick LR, Hall YN. et al Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988–2014. JAMA 2016; 316: 602 DOI: 10.1001/jama.2016.10924.
- 7 Sanghavi SF, Roark T, Zelnick LR. et al Histopathologic and Clinical Features in Patients with Diabetes and Kidney Disease. Kidney360 2020; 01: 1217-1225 DOI: 10.34067/KID.0003962020.
- 8 de Zeeuw D. Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy. Semin in Nephrol 2007; 27: 172-181 DOI: 10.1016/j.semnephrol.2007.01.002.
- 9 Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863
- 10 Chapter 1: Definition and classification of CKD Kidney Int Suppl. 2013; 03: 19-62 DOI: 10.1038/kisup.2012.64.
- 11 Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med 2019; 33: 363-382 DOI: 10.1111/jvim.15454.
- 12 Hommel E, Parving HH, Mathiesen E. et al Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986; 293: 467-470 DOI: 10.1136/bmj.293.6545.467.
- 13 Bjorck S, Nyberg G, Mulec H. et al Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293: 471-474 DOI: 10.1136/bmj.293.6545.471.
- 14 Heeg JE, de Jong PE, van der Hem GK. et al Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78-83 DOI: 10.1038/ki.1987.174.
- 15 Mittal N, Sehray V, Mittal R. et al Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. Eur J Pharmacol 2021; 907: 174320 DOI: 10.1016/j.ejphar.2021.174320.
- 16 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446 DOI: 10.1056/NEJMoa2024816.
- 17 The EMPA-KIDNEY Collaborative Group Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127 DOI: 10.1056/NEJMoa2204233.
- 18 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334 DOI: 10.1056/NEJMoa1515920.
- 19 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 DOI: 10.1056/NEJMoa1504720.
- 20 Cannon CP, Pratley R, Dagogo-Jack S. et al Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383: 1425-1435 DOI: 10.1056/NEJMoa2004967.
- 21 Neuen BL, Young T, Heerspink HJL. et al SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 07: 845-854 DOI: 10.1016/S2213-8587(19)30256-6.
- 22 Rossing P, Caramori ML, Chan JCN. et al KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102: S1-S127 DOI: 10.1016/j.kint.2022.06.008.
- 23 Rossing P, Caramori ML, Chan JCN. et al Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102: 990-999 DOI: 10.1016/j.kint.2022.06.013.
- 24 de Boer IH, Khunti K, Sadusky T. et al Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45: 3075-3090 DOI: 10.2337/dci22-0027.
- 25 Singh AK, Singh A, Singh R. et al Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Diabetes Metab Syndr 2022; 16: 102638 DOI: 10.1016/j.dsx.2022.102638.
- 26 Bakris GL, Agarwal R, Chan JC. et al Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015; 314: 884 DOI: 10.1001/jama.2015.10081.
- 27 Ong GSY, Young MJ. Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways. J Mol Endocrinol 2017; 58: R33-R57 DOI: 10.1530/JME-15-0318.
- 28 Sarafidis P, Iatridi F, Ferro C. et al Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J 2023; 16: 1885-1907 DOI: 10.1093/ckj/sfad139.
- 29 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229 DOI: 10.1056/NEJMoa2025845.
- 30 Pitt B, Filippatos G, Agarwal R. et al Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263 DOI: 10.1056/NEJMoa2110956.
- 31 Agarwal R, Filippatos G, Pitt B. et al Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484 DOI: 10.1093/eurheartj/ehab777..
- 32 Mosenzon O, Schechter M, Leibowitz G. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. Adv Chronic Kidney Dis 2021; 28: 347-360 DOI: 10.1053/j.ackd.2021.04.005.
- 33 Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009; 373: 438-439 DOI: 10.1016/S0140-6736(08)61247-7.
- 34 Marso SP, Bain SC, Consoli A. et al Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844 DOI: 10.1056/NEJMoa1607141.
- 35 Shaman AM, Bain SC, Bakris GL. et al Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials. Circulation 2021; 145: 575-585 DOI: 10.1161/CIRCULATIONAHA.121.055459.
- 36 Wanner C, Heerspink HJL, Zinman B. et al Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol 2018; 29: 2755-2769 DOI: 10.1681/ASN.2018010103.
- 37 Husain M, Birkenfeld AL, Donsmark M. et al Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019; 381: 841-851 DOI: 10.1056/NEJMoa1901118.
- 38 Novo Nordisk Pharma GmbH. Im Internet. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167028 Stand: 12.03.2024
- 39 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 DOI: 10.1056/NEJMoa1603827.
- 40 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 839-848 DOI: 10.1056/NEJMoa1616011.
- 41 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130 DOI: 10.1016/S0140-6736(19)31149-3.
- 42 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet 2019; 394: 131-138 DOI: 10.1016/S0140-6736(19)31150-X.
- 43 Mann JFE, Buse JB, Idorn T. et al Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab 2021; 23: 2058-2066 DOI: 10.1111/dom.14443.
- 44 Holman RR, Bethel MA, Mentz RJ. et al Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228-1239 DOI: 10.1056/NEJMoa1612917.